Cardiology
Cardiac Amyloidosis Has a Diagnostic Grey Zone. A New PET Tracer Could Help Close It
A Phase III study of iodine-124 evuzamitide PET/CT reported 94% sensitivity and 86% specificity for cardiac amyloidosis across ATTR and AL disease. The investigational tracer could eventually give clinicians another option when existing imaging and laboratory pathways leave the diagnosis unresolved, but regulatory approval and real-world positioning still lie ahead. JAMA Network
Half of CKM patients go untreated and most fail control
Sleep is now cardiovascular prevention. Health systems still treat it like lifestyle advice
Pharmacists are becoming the front door for cardiometabolic care. Policy is still treating them like the back office
New nicotine products could become the next major cardiovascular policy failure
Cardiac rehab saves lives. Health systems still treat it like optional aftercare
Resistant hypertension may need a diagnostic revolution, not just another drug
Heart pumps save lives. FDA’s latest Impella alerts show why cardiac device safety cannot stop at approval.
Gene therapy is entering cardiology. Friedreich ataxia shows why rare heart disease may be the first test
Europe’s next stroke bet: can Factor XIa inhibition change prevention without raising bleeding risk?
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Cardiology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases